These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 23969404)

  • 41. [Complete remission by sorafenib for local reccurence of renal cell carcinoma with a tempraly elevation of C-reactive protein: a case report].
    Yoshinaga A; Ichiyanagi N; Kamata S
    Nihon Hinyokika Gakkai Zasshi; 2013 Jul; 104(4):609-11. PubMed ID: 23971370
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Hand-foot skin reaction in patients treated with sorafenib: a clinicopathological study of cutaneous manifestations due to multitargeted kinase inhibitor therapy.
    Yang CH; Lin WC; Chuang CK; Chang YC; Pang ST; Lin YC; Kuo TT; Hsieh JJ; Chang JW
    Br J Dermatol; 2008 Mar; 158(3):592-6. PubMed ID: 18070211
    [TBL] [Abstract][Full Text] [Related]  

  • 43. [Stevens-Johnson syndrome induced by regorafenib in a patient with progressive recurrent rectal carcinoma].
    Mihara Y; Yamaguchi K; Nakama T; Nakayama G; Kamei H; Ishibashi N; Uchida S; Akagi Y; Ogata Y
    Gan To Kagaku Ryoho; 2015 Feb; 42(2):233-6. PubMed ID: 25743146
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Initial Experience of Sorafenib Neoadjuvant Therapy Combined with Retroperitoneoscopy in Treating T2 Large Renal Carcinoma.
    Lin CH; Yuan HJ; Wang K; Wu JT; Liu QZ; Yu SQ; Men CP; Gao ZL; Wang J
    Biomed Res Int; 2015; 2015():609549. PubMed ID: 26421296
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma: subanalyses of a phase III trial.
    Bruix J; Raoul JL; Sherman M; Mazzaferro V; Bolondi L; Craxi A; Galle PR; Santoro A; Beaugrand M; Sangiovanni A; Porta C; Gerken G; Marrero JA; Nadel A; Shan M; Moscovici M; Voliotis D; Llovet JM
    J Hepatol; 2012 Oct; 57(4):821-9. PubMed ID: 22727733
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Effects of antiangiogenic therapy.
    von Falck C; Wacker F; Rosenthal H
    J Vasc Interv Radiol; 2012 Nov; 23(11):1503. PubMed ID: 23101922
    [No Abstract]   [Full Text] [Related]  

  • 47. Sorafenib-induced erythema multiforme in metastatic renal cell carcinoma.
    Bilaç C; Müezzinoğlu T; Ermertcan AT; Kayhan TC; Temeltaş G; Oztürkcan S; Temiz P
    Cutan Ocul Toxicol; 2009; 28(2):90-2. PubMed ID: 19514932
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Severe Skin Disorders Due to Sorafenib Use After Nivolumab Treatment in Renal Cell Carcinoma Patients.
    Koide H; Noda S; Yoshida T; Kageyama S; Teramura K; Kato T; Kawauchi A; Fujimoto N; Terada T
    In Vivo; 2021; 35(5):2969-2974. PubMed ID: 34410996
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Successful use of sorafenib after bortezomib failure in metastatic follicular thyroid cancer - a case report.
    Eisner F; Schaberl-Moser R; Gerger A; Samonigg H; Pichler M
    Onkologie; 2013; 36(6):368-70. PubMed ID: 23774152
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Long-term response of over ten years with sorafenib monotherapy in metastatic renal cell carcinoma: a case report.
    Ueda K; Suekane S; Ogasawara N; Chikui K; Suyama S; Nakiri M; Nishihara K; Matsuo M; Igawa T
    J Med Case Rep; 2016 Jun; 10():177. PubMed ID: 27312478
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Risk factors for sorafenib-induced high-grade skin rash in Japanese patients with advanced renal cell carcinoma.
    Tsuchiya N; Narita S; Inoue T; Hasunuma N; Numakura K; Horikawa Y; Satoh S; Notoya T; Fujishima N; Hatakeyama S; Ohyama C; Habuchi T
    Anticancer Drugs; 2013 Mar; 24(3):310-4. PubMed ID: 23237922
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Pharmacokinetic interaction between sorafenib and prednisolone in a patient with hepatocellular carcinoma.
    Noda S; Shioya M; Hira D; Fujiyama Y; Morita SY; Terada T
    Cancer Chemother Pharmacol; 2013 Jul; 72(1):269-72. PubMed ID: 23673446
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Phase II escalation study of sorafenib in patients with metastatic renal cell carcinoma who have been previously treated with anti-angiogenic treatment.
    Mancuso A; Di Paola ED; Leone A; Catalano A; Calabrò F; Cerbone L; Zivi A; Messina C; Alonso S; Vigna L; Caristo R; Sternberg CN
    BJU Int; 2012 Jan; 109(2):200-6. PubMed ID: 22212284
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Tivozanib for the treatment of metastatic renal cancer.
    Wong HH; Eisen T
    Expert Rev Anticancer Ther; 2013 Jun; 13(6):649-60. PubMed ID: 23773100
    [TBL] [Abstract][Full Text] [Related]  

  • 55. A randomized phase II trial of maintenance therapy with Sorafenib in front-line ovarian carcinoma.
    Herzog TJ; Scambia G; Kim BG; Lhommé C; Markowska J; Ray-Coquard I; Sehouli J; Colombo N; Shan M; Petrenciuc O; Oza A
    Gynecol Oncol; 2013 Jul; 130(1):25-30. PubMed ID: 23591401
    [TBL] [Abstract][Full Text] [Related]  

  • 56. [Erythema multiforme vs. Stevens-Johnson syndrome and toxic epidermal necrolysis: an important diagnostic distinction].
    Rabelink NM; Brakman M; Maartense E; Bril H; Bakker-Wensveen CA; Bavinck JN
    Ned Tijdschr Geneeskd; 2003 Oct; 147(43):2089-94. PubMed ID: 14619195
    [TBL] [Abstract][Full Text] [Related]  

  • 57. The influence of genetic variants of sorafenib on clinical outcomes and toxic effects in patients with advanced renal cell carcinoma.
    Qin C; Cao Q; Li P; Wang S; Wang J; Wang M; Chu H; Zhou L; Li X; Ye D; Zhang H; Huang Y; Dong B; Sun X; Zou Q; Cai H; Sun L; Zhu J; Liu F; Ji J; Cui L; Wang X; Zhou H; Zhao H; Wu B; Chen J; Jiang M; Zhang Z; Shao P; Ju X; Yin C
    Sci Rep; 2016 Feb; 6():20089. PubMed ID: 26830973
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Cost-effectiveness of sorafenib compared to best supportive care in second line renal cell cancer from a payer perspective in Cyprus.
    Petrou PK; Talias MA
    Expert Rev Pharmacoecon Outcomes Res; 2014 Feb; 14(1):131-8. PubMed ID: 24397606
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Toxic Effects of Sorafenib in Patients With Differentiated Thyroid Carcinoma Compared With Other Cancers.
    Jean GW; Mani RM; Jaffry A; Khan SA
    JAMA Oncol; 2016 Apr; 2(4):529-34. PubMed ID: 26847808
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Hand-foot-skin reaction related to use of the multikinase inhibitor sorafenib and hard orthotics.
    Kusari A; Borok J; Han AM; Valderrama AJ; Friedlander SF
    Pediatr Dermatol; 2018 Jul; 35(4):e206-e209. PubMed ID: 29766555
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.